S&P 500   4,229.75 (-1.37%)
DOW   33,025.59 (-1.22%)
QQQ   354.94 (-1.75%)
AAPL   172.04 (-0.98%)
MSFT   312.64 (-2.85%)
META   300.12 (-2.18%)
GOOGL   132.80 (-1.02%)
AMZN   124.91 (-3.51%)
TSLA   247.59 (-1.59%)
NVDA   436.23 (-2.59%)
NIO   8.68 (-1.25%)
BABA   84.55 (-2.29%)
AMD   100.23 (-2.94%)
T   14.70 (+0.20%)
F   12.06 (-2.03%)
MU   68.11 (+0.22%)
CGC   0.69 (-5.79%)
GE   107.62 (-1.08%)
DIS   79.99 (-2.06%)
AMC   8.05 (-1.23%)
PFE   34.04 (+0.29%)
PYPL   57.61 (-1.62%)
NFLX   376.06 (-1.12%)
S&P 500   4,229.75 (-1.37%)
DOW   33,025.59 (-1.22%)
QQQ   354.94 (-1.75%)
AAPL   172.04 (-0.98%)
MSFT   312.64 (-2.85%)
META   300.12 (-2.18%)
GOOGL   132.80 (-1.02%)
AMZN   124.91 (-3.51%)
TSLA   247.59 (-1.59%)
NVDA   436.23 (-2.59%)
NIO   8.68 (-1.25%)
BABA   84.55 (-2.29%)
AMD   100.23 (-2.94%)
T   14.70 (+0.20%)
F   12.06 (-2.03%)
MU   68.11 (+0.22%)
CGC   0.69 (-5.79%)
GE   107.62 (-1.08%)
DIS   79.99 (-2.06%)
AMC   8.05 (-1.23%)
PFE   34.04 (+0.29%)
PYPL   57.61 (-1.62%)
NFLX   376.06 (-1.12%)
S&P 500   4,229.75 (-1.37%)
DOW   33,025.59 (-1.22%)
QQQ   354.94 (-1.75%)
AAPL   172.04 (-0.98%)
MSFT   312.64 (-2.85%)
META   300.12 (-2.18%)
GOOGL   132.80 (-1.02%)
AMZN   124.91 (-3.51%)
TSLA   247.59 (-1.59%)
NVDA   436.23 (-2.59%)
NIO   8.68 (-1.25%)
BABA   84.55 (-2.29%)
AMD   100.23 (-2.94%)
T   14.70 (+0.20%)
F   12.06 (-2.03%)
MU   68.11 (+0.22%)
CGC   0.69 (-5.79%)
GE   107.62 (-1.08%)
DIS   79.99 (-2.06%)
AMC   8.05 (-1.23%)
PFE   34.04 (+0.29%)
PYPL   57.61 (-1.62%)
NFLX   376.06 (-1.12%)
S&P 500   4,229.75 (-1.37%)
DOW   33,025.59 (-1.22%)
QQQ   354.94 (-1.75%)
AAPL   172.04 (-0.98%)
MSFT   312.64 (-2.85%)
META   300.12 (-2.18%)
GOOGL   132.80 (-1.02%)
AMZN   124.91 (-3.51%)
TSLA   247.59 (-1.59%)
NVDA   436.23 (-2.59%)
NIO   8.68 (-1.25%)
BABA   84.55 (-2.29%)
AMD   100.23 (-2.94%)
T   14.70 (+0.20%)
F   12.06 (-2.03%)
MU   68.11 (+0.22%)
CGC   0.69 (-5.79%)
GE   107.62 (-1.08%)
DIS   79.99 (-2.06%)
AMC   8.05 (-1.23%)
PFE   34.04 (+0.29%)
PYPL   57.61 (-1.62%)
NFLX   376.06 (-1.12%)
NASDAQ:HCM

HUTCHMED (HCM) Stock Forecast, Price & News

$16.46
-0.26 (-1.56%)
(As of 01:27 PM ET)
Compare
Today's Range
$16.40
▼
$16.66
50-Day Range
$13.22
▼
$16.95
52-Week Range
$7.39
▼
$21.28
Volume
17,654 shs
Average Volume
160,492 shs
Market Capitalization
$2.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00
ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

HUTCHMED MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
201.6% Upside
$50.00 Price Target
Short Interest
Healthy
0.47% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of HUTCHMED in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.03) to ($0.57) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

624th out of 975 stocks

Pharmaceutical Preparations Industry

289th out of 454 stocks

See Top Rated MarketRank™ Stocks Here

HCM stock logo

About HUTCHMED (NASDAQ:HCM) Stock

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

HCM Price History

HCM Stock News Headlines

October 3, 2023 | finance.yahoo.com
Wall Street Analysts See a 107.24% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
September 24, 2023 | americanbankingnews.com
HUTCHMED (NASDAQ:HCM) Trading Up 4.3%
October 3, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
September 12, 2023 | finance.yahoo.com
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
August 21, 2023 | msn.com
Hutchmed's Candidate Achieves Main Goal In China's Rare Blood Disorder Study
August 20, 2023 | markets.businessinsider.com
HUTCHMED : Sovleplenib Phase III ESLIM-01 Study Meets Main Goal In Primary Immune Thrombocytopenia
August 20, 2023 | finance.yahoo.com
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
August 13, 2023 | ca.finance.yahoo.com
HCM - HUTCHMED (China) Limited
October 3, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
July 31, 2023 | finanznachrichten.de
HUTCHMED (China) Limited: HUTCHMED Reports 2023 Interim Results and Provides Business Updates
July 31, 2023 | finance.yahoo.com
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
July 19, 2023 | finance.yahoo.com
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
July 13, 2023 | benzinga.com
HUTCHMED Announces Changes to Board of Directors and Technical Committee
July 13, 2023 | finance.yahoo.com
HUTCHMED Announces Changes to Board of Directors and Technical Committee
June 15, 2023 | finance.yahoo.com
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
June 9, 2023 | finance.yahoo.com
HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
June 6, 2023 | au.finance.yahoo.com
HCM.L - HUTCHMED (China) Limited
May 12, 2023 | finance.yahoo.com
HUTCHMED Announces Board of Directors and Board Committee Membership
May 12, 2023 | finance.yahoo.com
HUTCHMED Announces Board of Directors and Board Committee Membership
May 7, 2023 | seekingalpha.com
Our Update On Hutchmed China's Progress
April 17, 2023 | finance.yahoo.com
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
April 11, 2023 | finance.yahoo.com
HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
April 4, 2023 | finance.yahoo.com
HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations
March 12, 2023 | finance.yahoo.com
HUTCHMED Confirms No Assets Held at Silicon Valley Bank
January 23, 2023 | finance.yahoo.com
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
January 23, 2023 | markets.businessinsider.com
Takeda To Pay Up To $1.13 Bln To HUTCHMED For Exclusive License Of Fruquintinib Outside China
January 1, 2023 | finance.yahoo.com
HUTCHMED (China) Limited (HCM)
See More Headlines
Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

HCM Company Calendar

Today
10/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HCM
CUSIP
N/A
CIK
1648257
Web
www.chi-med.com
Phone
852-2121-3888
Fax
852-2128-1778
Employees
2,025
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$50.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+203.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
3.20
Quick Ratio
3.04

Sales & Book Value

Annual Sales
$757.24 million
Price / Sales
3.79
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.68 per share
Price / Book
4.48

Miscellaneous

Outstanding Shares
174,198,000
Free Float
167,927,000
Market Cap
$2.87 billion
Optionable
Not Optionable
Beta
1.01

Social Links

7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Chi Keung To ACGI (Age 71)
    B.Sc., BSc, M.B.A., MBA, Exec. Chairman
    Comp: $85k
  • Dr. Wei-Guo Su B.Sc. (Age 65)
    Ph.D., CEO, Chief Scientific Officer & Exec. Director
    Comp: $1.97M
  • Mr. Chig Fung Cheng BEc (Age 56)
    CA, CFO & Exec. Director
    Comp: $886k
  • Ms. Edith Shih BSE (Age 71)
    C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., MA, Company Sec. & Non-Exec. Director
  • Dr. Karen Jane Atkin (Age 57)
    Exec. VP & COO
  • Mr. Kin Hung Lee M.B.A. (Age 46)
    Sr. VP of Corp. Fin. & Devel.
  • Mr. Charles George Rupert Nixon (Age 53)
    Group Gen. Counsel
  • Ms. Selina Zhang
    Sr. VP of Global HR
  • Dr. Qingmei Wang Ph.D. (Age 60)
    Sr. VP of Bus. Devel. & Strategic Alliances
  • Mr. Hong Chen (Age 53)
    Sr. VP & Chief Commercial Officer- China

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













HCM Stock - Frequently Asked Questions

Should I buy or sell HUTCHMED stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HCM shares.
View HCM analyst ratings or view top-rated stocks.

What is HUTCHMED's stock price forecast for 2023?

2 brokers have issued 12 month price targets for HUTCHMED's stock. Their HCM share price forecasts range from $50.00 to $50.00. On average, they expect the company's stock price to reach $50.00 in the next year. This suggests a possible upside of 203.4% from the stock's current price.
View analysts price targets for HCM or view top-rated stocks among Wall Street analysts.

How have HCM shares performed in 2023?

HUTCHMED's stock was trading at $14.78 at the beginning of 2023. Since then, HCM stock has increased by 11.5% and is now trading at $16.48.
View the best growth stocks for 2023 here.

Are investors shorting HUTCHMED?

HUTCHMED saw a decrease in short interest in September. As of September 15th, there was short interest totaling 821,400 shares, a decrease of 11.5% from the August 31st total of 928,000 shares. Based on an average daily volume of 108,800 shares, the short-interest ratio is presently 7.5 days.
View HUTCHMED's Short Interest.

What ETFs hold HUTCHMED's stock?

ETFs with the largest weight of HUTCHMED (NASDAQ:HCM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Telford Homes (TEF), AbbVie (ABBV), Exelixis (EXEL), GW Pharmaceuticals (GWPH), Premier Oil (PMO), CRISPR Therapeutics (CRSP), AT&T (T), Johnson & Johnson (JNJ), NVIDIA (NVDA) and Weyerhaeuser (WY).

When did HUTCHMED IPO?

(HCM) raised $100 million in an IPO on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

What is HUTCHMED's stock symbol?

HUTCHMED trades on the NASDAQ under the ticker symbol "HCM."

How do I buy shares of HUTCHMED?

Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HUTCHMED's stock price today?

One share of HCM stock can currently be purchased for approximately $16.48.

How much money does HUTCHMED make?

HUTCHMED (NASDAQ:HCM) has a market capitalization of $2.87 billion and generates $757.24 million in revenue each year.

How many employees does HUTCHMED have?

The company employs 2,025 workers across the globe.

How can I contact HUTCHMED?

HUTCHMED's mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The official website for the company is www.chi-med.com. The company can be reached via phone at 852-2121-3888, via email at ir@chi-med.com, or via fax at 852-2128-1778.

This page (NASDAQ:HCM) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -